Physician profile
Benjamin Helgemo
NPI 1366424376
$2,226.81
in general payments reported to CMS, 2019-2025
16 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $212 · 2021: $401 · 2022: $147 · 2023: $388 · 2024: $532 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $461.22 | 2019-2025 | Dyanavel Xr, Onyda Xr, Quillichew Er |
| Pfizer INC. | $376.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $316.49 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Corium, LLC | $176.48 | 2023-2024 | Azstarys |
| Sanofi Pasteur INC. | $171.54 | 2024 | |
| Ironshore Pharmaceuticals INC. | $169.92 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $108.09 | 2019-2025 | Bexsero |
| Supernus Pharmaceuticals, INC. | $101.26 | 2021-2023 | Qelbree |
| Kaleo, INC. | $96.84 | 2020-2022 | |
| Sobi, INC | $68.66 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.44 | 2020-2021 | |
| Genzyme Corporation | $37.13 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $28.59 | 2024 | Flumist Quadrivalent |
| Biomarin Pharmaceutical INC. | $21.87 | 2024 | Voxzogo 1.2mg |
| Shire North American Group INC | $17.62 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $15.03 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Helgemo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.